DocDollars

Intercept Pharmaceuticals, Inc.

NJ · United States · Reporting entity ID 100000151645

Total reported 2019–2025
$116.4M
#84 of 2,960 reporting companies — 0.1% of all reported industry payments
$18.4M in general payments across 76,009 records, plus $97.3M in research funding across 18,027 records.

How it breaks down

General payments $18,373,120
Research funding $97,259,943
Ownership & investment $767,060

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Intercept Pharmaceuticals, Inc. reported $116.4M to US doctors and teaching hospitals from 2019 to 2025, ranking #84 of 2,960 reporting companies. 84% of that was research funding and 16% general payments such as consulting, speaking, food and travel. 76,009 general payment records and 18,027 research records were filed.

Common questions about Intercept Pharmaceuticals, Inc.

How much has Intercept Pharmaceuticals, Inc. paid US doctors?

Intercept Pharmaceuticals, Inc. reported $116,400,122 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $18,373,120 in general payments, $97,259,943 in research funding and $767,060 in ownership and investment interests.

How does Intercept Pharmaceuticals, Inc. rank among drug and device companies?

It ranks #84 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Intercept Pharmaceuticals, Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.